@Veeva Systems

This year’s Veeva R&D and Quality Summit in Madrid, accentuated the current trends and needs of the pharma and life sciences industries.

© Santhera Pharmaceuticals

Santhera Pharmaceuticals Holding has exclusively granted the rights to commercialise its Duchenne muscular dystrophy drug vamorolone in North America to Catalyst Pharmaceuticals Inc.

Clinical development of Bone Therapeutics' lead asset, the bone forming cell therapy ALLOB, will be discontinued. © Pixabay.com/virnuls

BioSenic SA has  suspended its Phase II proof-of-concept trial on fracture healing with its allogeneic cell therapy ALLOB.

EpiTcer platform. Neoantigen-loaded beads are phagocytised by DCs and present antigens to T-cells which in turn are activated. © NEOGAP Therapeutics

Swedish personalised immunotherapy specialist Neogap Therapeutics AB has acquired the remaining shares of its subsidiary, TCER Oncology AB through two new shareholders.

Hantavirus. © CDC/Cynthia Goldsmith

An international research team headed by Pablo Guardado-Calvo at Institut Pasteur Paris has demonstrated evaluated antibody efficacy against lethal hantaviruses.

©?Selvita S.A.

The new Krakow headquarters of preclinical CRO Selvita have opened.

The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital.
3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing for biological drugs advances its international expansion with the opening of its first commercial office in the United States located in Boston, Massachusetts.

Experts called on to move forward rapidly at the 7th AMR Conference in Basel. Picture: ©?bamconn GmbH/Thorsten Biernath

How to stop the silent pandemic AMR was discussed by 500 experts from 13 countries at the 7th AMR Conference in Basel. At that time, in Brussels, there were two proposals on the table on how to compensate novel resistance-breaking antimicrobials, from which one got the green light in the new pharma legislation.

© Syncona

Syncona Ltd had spun-out the ophtalmology specialist Beacon Therapeutics Holdings Ltd with a £96m Series A financing.

Eculizumab (Soliris) is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica.  © Naingwaiwin/wikimedia.com

Roche AG has announced positive results from the non-blinded Phase III COMMODORE 1 and 2 trials at the EHA Hybrid Congress in Frankfurt, Germany.